Cara Therapeutics, Inc.(CARA): For the most recent quarter end, Cara Therapeutics, Inc. reported Annual Earnings of $-0.42. Based on the filings, last years Annual Earnings was, $-1. For the most recent quarter end, CARA reported a surprise Earnings per Share of 14.29% . The consensus estimate for current quarter is $-0.51 and for the current fiscal year, the estimate is $-1.81. For the Next fiscal year, the estimate is $-1.76 based on the consensus.
Cara Therapeutics Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-0.42 EPS for the quarter, beating the analyst consensus estimate by $ 0.05. Analyst had a consensus of $-0.47.Analysts expectations of $ .09.During the same quarter in the previous year, the company posted $-0.19 EPS.
Company has reported several Insider transactions to the SEC, on Apr 20, 2016, Frederique Ph.d. Menzaghi (VP-Research & Development) sold 6,000 shares at 9.00 per share price.On Jan 27, 2016, Michael E Lewis (Chief Scientific Advisor) sold 7,262 shares at 10.93 per share price.On Jan 12, 2016, Dean Slagel (director) sold 44,000 shares at 17.00 per share price.
Cara Therapeutics, Inc. (NASDAQ:CARA) witnessed a decline in the market cap on Wednesday as its shares dropped 1.02% or 0.15 points. After the session commenced at $14.85, the stock reached the higher end at $14.8851 while it hit a low of $14.22. With the volume soaring to 1,092,840 shares, the last trade was called at $14.55. The company has a 52-week high of $17.2. The company has a market cap of $397 million and there are 27,282,863 shares in outstanding. The 52-week low of the share price is $4.26.
Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.